Paper36757706
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M and 28 others. JAMA Oncol, 2023. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. Papers, record 36757706. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36757706
- Disease
- acute myeloid leukemia587 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
- PubMed
- Publication types
- Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cell Transplantation | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Male | |
| Middle Aged | |
| Adolescent | |
| Young Adult | |
| Adult | |
| Female | |
| Consolidation Chemotherapy | |
| Quality of Life | |
| Transplantation, Homologous | |
| Remission Induction | |
| Recurrence |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01246752 | Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42886311 | Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42886311 | PubMed |
| 42821026 | FLT3-Mutated AML: Transplanting with Precision in the Targeted Era. | Curr Hematol Malig Rep | 2026 | https://conductscience.org/library/papers/42821026 | PubMed |
| 42812306 | Allogeneic hematopoietic stem cell transplantation is associated with improved survival compared with chemotherapy in patients with acute myeloid leukemia harboring favorable-risk genetic features at initial diagnosis: a single-center retrospective study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42812306 | PubMed |
| 42640163 | Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia. | NEJM Evid | 2026 | https://conductscience.org/library/papers/42640163 | PubMed |
| 42471330 | Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42471330 | PubMed |
| 42410464 | Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42410464 | PubMed |
| 42346269 | Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42346269 | PubMed |
| 42271520 | Circadian rhythm-guided cellular therapy in hematologic malignancies: mechanisms, clinical evidence, and optimization strategies. | Biomark Res | 2026 | https://conductscience.org/library/papers/42271520 | PubMed |
| 42007253 | Artificial intelligence-based prognostic models in acute myeloid leukemia: systematic review and meta-analysis. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42007253 | PubMed |
| 41914434 | Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. | Cancer | 2026 | https://conductscience.org/library/papers/41914434 | PubMed |
| 41686261 | Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41686261 | PubMed |
| 41596709 | Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596709 | PubMed |
| 41509995 | Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/41509995 | PubMed |
| 41274886 | Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study. | Blood Cancer J | 2025 | https://conductscience.org/library/papers/41274886 | PubMed |
| 41139710 | Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review. | Ann Hematol | 2025 | https://conductscience.org/library/papers/41139710 | PubMed |
| 41131586 | High IL1R1 expression predicts poor survival and benefit from stem cell transplant in intermediate-risk acute myeloid leukemia from the Leucegene cohort. | Biomark Res | 2025 | https://conductscience.org/library/papers/41131586 | PubMed |
| 40720773 | Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. | Blood Adv | 2025 | https://conductscience.org/library/papers/40720773 | PubMed |
| 40668660 | Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia. | Blood Adv | 2025 | https://conductscience.org/library/papers/40668660 | PubMed |
| 40584630 | Identification of an Ara-C resistance-related gene risk score and the role of S100A4 in AML via NR6A1-dependent activation and p53 regulation. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40584630 | PubMed |
| 40534491 | TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Haematologica | 2025 | https://conductscience.org/library/papers/40534491 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CEBPA | 1050 | PubTator's text mining | https://conductscience.org/library/genes/1050 | NCBI Gene |
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| CYTARABINE | CHEMBL803 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL803 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36757706
GET https://conductscience.org/api/papers/v1/36757706/authors?page=2